Chelmsford, MA (March 13th, 2019) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the addition of Dr. Stephen Brecher to the company’s world-class, international Clinical Advisory Board.
“Stephen is an internationally recognized expert for his work with C. difficile infections and antibiotic resistance,” said David Macdonald, CEO of First Light Diagnostics. “His years of experience in microbiology and diagnostics will provide valuable insight to our development and commercialization efforts.”
Also known as the “Chief of Staph”, Dr. Brecher has been practicing clinical microbiology for 50 years. He is the Director of Microbiology at the VA Boston HealthCare System and is an Associate Professor of Pathology and Laboratory Medicine at the Boston University School of Medicine. He is on the editorial board of the Journal of Clinical Microbiology and has chaired/convened a workshop on antibiotic resistance at the annual meetings of the American Society for Microbiology for 20 years.
Most recently (January 2019) Dr. Brecher gave a TEDx talk on bacteria (“To see three pounds of bacteria, look in the mirror”).
“I was excited to be invited to participate as part of the First Light Diagnostics Clinical Advisory Board,” said Dr. Brecher. “First Light’s use of technology to diagnose and determine the right course of treatment could turn the tide in the battle against antibiotic resistance.”
Dr. Brecher joins a diverse group of industry luminaries that include Dr. Ciarán P. Kelly, Dr. Mark Wilcox, Dr. Dale N. Gerding, and Dr. James Kirby. This world-class advisory group sees the value First Light Diagnostics can bring to medicine and are tasked with guiding the company through development and commercialization.
About First Light Diagnostics
First Light Diagnostics is developing and preparing to commercialize, innovative diagnostic products for rapid, sensitive and cost-saving detection of life-threatening infections, and for combating the spread of antibiotic resistance. Don Straus is the company’s Founder and primary inventor of the company’s core scientific technology. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the clinical performance of the most advanced commercial laboratory tests with speed, cost-effectiveness, and ease-of-use. The tests rapidly detect infections, identify infectious agents, and determine effective targeted antibiotic therapy. This will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics. To learn more, please visit: www.firstlightdx.com
President and CEO
First Light Diagnostics
Mobile: (858) 997-9641